Abstract: Assess the 10-year Immune persistence and the predictors after primary vaccination hepatitis B vaccine (HepB) among normal and high-responder infants. A total of 1 838 Infants of 7-12 months old located in Jinan, Weifang, Yantai and Weihai of Shandong Province who were induced normal or high antibody response (anti-HBs titer ≥ 100 mIU/ml) after primary vaccination (three dose with 0-1-6 procedure) with 5 μg recombinant HepB among newborns were included in the study, in 2009. 3 ml of venous blood samples were collected at baseline survey (T) and antibodies against hepatitis B surface antigen (anti-HBs), antibody against hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were detected using chemiluminescence microparticle immunoassay (CMIA) method. A self-designed questionnaire was used to collect information including the infant's age, sex, birth weight, premature birth, birth number, delivery location and mother's HBV infection status. In 2014 (followed up for 5 years) and in 2019 (followed up for 10 years) (T), 2 ml of venous blood samples were collected. Anti HBS and anti HBC were detected by CMIA method. Those with anti HBS<10 mIU/ml were detected by CMIA method. Multivariate unconditional logistic and linear regression models were used to analyze the influencing factors of anti-HBs positive rate and geometric mean concentration (GMC) at T. After 10 years follow-up, 73.94% of the subjects (1 359/1 835) finished the follow-up. 51.15% of the subjects, a total of 625 were boys. The positive rate of anti-HBs was 100% at T and decreased to 53.44% (95%: 50.59%-56.26%) at T. The average annual decline rate of anti-HBs positive rate from T to T was 6.07%. The GMC of anti-HBs decreased from 607.89 (95%: 579.01-642.62) mIU/ml to 16.44 (95%: 15.06-18.00) mIU/ml. The average annual decline rate of anti-HBs GMC in 10-year follow-up was 30.30%. Multivariate logistic analysis showed that the positive rate of anti-HBs at T was lower in those who did not vaccinate the first dose in time (=0.25, 95%:0.07-0.71). Compared with those with GMC<1 000 mIU/ml at T, those with GMC ≥ 1 000 mIU/ml had a higher positive rate of anti-HBs at T (=2.29, 95%:1.76-2.97). Multivariate regression analysis showed that the GMC of anti-HBs at T was lower in those who did not vaccinate the first dose in time (β=-0.50, 95%:-1.24-0.24). Compared with those with GMC<1 000 mIU/ml at T, those with GMC ≥ 1 000 mIU/ml had a higher GMC of anti-HBs at T (β=0.81, 95%: 0.62-1.05). Anti-HBs GMC decreased in 10 years after primary vaccination of 5 μg recombinant hepatitis B vaccine among normal and high-responders. The anti-HBs persistence was mainly associated with whether the first dose was vaccinated in time and the level of anti-HBs at the end of primary vaccination.

Comparison of Long-Term Immunogenicity (23 Y) of 10 Μg and 20 Μg Doses of Hepatitis B Vaccine in Healthy Children

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Antibody Levels and Immune Memory 23 Years after Primary Plasma-Derived Hepatitis B Vaccination: Results of a Randomized Placebo-Controlled Trial Cohort from China Where Endemicity is High

[Effect of Plasma-Derived Hepatitis B Vaccine 23(rd) Year after a Full Course of Vaccination in Healthy Young Children].

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Immunological Effects of a 10-Μg Dose of Domestic Hepatitis B Vaccine in Adults

Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

[Comparison of Antibody Persistence after Primary Immunization with 5 Μg and 10 Μg Recombinant Hepatitis B Vaccine among Newborns with Normal and High Response: a Five-Year Following-Up].

Comparative Immunogenicity of a High-Dose Hepatitis B Virus (HBV) Vaccine with Rapid Immunization vs. Standard Schedule in HBV Vaccine—Naïve Adults Aged 25–55 in China

Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study.

[Anti-HBs persistence after primary vaccination with three doses of 5 μg recombinant hepatitis B vaccine among normal and high-responder infants: 10-year of follow-up].

Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country

[Valuation on the Immunization Efficacy on the 23 Years Who Had Received Plasma-Derived HBV Vaccine As Newborns].

Comparison of the effectiveness four years after Homo/Hetero prime-boost with 10 μg HP and 20 μg CHO recombinant hepatitis B vaccine at 1 and 6 months in maternal HBsAg-negative children

Long-term efficacy and immunological memory of plasma-derived hepatitis B vaccine 11 years after initial inoculation

The long-term efficacy of recombinant hepatitis B vaccines for children

Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China